We are monitoring the impact of COVID-19 on Latin America Cardiovascular Therapeutic Drugs Market Get in touch with us for detailed analysis Know More
Pulished Date February, 2020
ID: 1354
Share on
Share on

Latin America Cardiovascular Therapeutic Drugs Market Research Report – Segmented By Disease, Drug Class & Country (Brazil, Mexico, Argentina, Chile and Rest of Latin America) - Industry Analysis, Size, Share, Growth, Trends, And Forecast (2020 to 2025)

Pulished: February, 2020
ID: 1354
Pages: 145

The size of the Latin American Cardiovascular Therapeutic Drugs Market is currently worth USD 14.57 billion in 2020 and is projected to reach USD 16.01 billion by 2025, growing at a CAGR of 1.9%. The past few decades have witnessed significant success in the development of highly effective drug therapies for common cardiovascular disease. The widespread use of these therapies along with the rising cardiovascular disease accounts for the increasing market for cardiovascular therapeutics.

Cardiovascular therapeutic drugs are the prescribed drugs and medicines for the diseases that are related to the structure and function of the heart and blood vessels. Cardiovascular diseases are responsible for majority of the deaths globally and continues to cause health problems. These health problems mainly include heart failure, blood clots, coronary artery disease, high cholesterol and others.

The market is driven by a host of factors which includes rise in aging population, rise in per capita spending on healthcare and epidemic of general medical issues like obesity and diabetes. With cardiovascular disorders being the most common cause for morbidity and mortality, the market has a tremendous value and continue to do so in the coming years. However, there are a few restraints the market likes to overcome which includes rising costs for drug development and lowering of target population. And also, despite of high prevalence, drug development pipelines for cardiovascular disorders has been stagnant for a variety of reasons.

Latin America market for cardiovascular therapeutic drugs market is segmented into diseases and drug class. Based on the type of cardiovascular diseases, the market is studied as hypertension, thrombosis, hyperlipidaemia, Arteriosclerosis, Coronary artery disease, Peripheral artery disease, Cardiac arrhythmias, acute coronary syndrome, Myocardial infarction, cardiac failure diseases and other diseases. Asia-Pacific market based on its geographical regions, is segmented into Brazil, Mexico, Argentina and Others.

Some of the leading companies in Cardiovascular Therapeutics Drugs Market includes Johnson & Johnson, Bayer, AstraZeneca, Novartis, Bristol-Myers Squibb, Takeda, Merck, Pfizer Sanofi, and boehringer ingelheim.

1. Introduction                                 

                1.1 Market Definition                    

                1.2 Study Deliverables                  

                1.3 Base Currency, Base Year and Forecast Periods                           

                1.4 General Study Assumptions                

2. Research Methodology                                           

                2.1 Introduction                              

                2.2 Research Phases                      

                                2.2.1 Secondary Research            

                                2.2.2 Primary Research 

                                2.2.3 Econometric Modelling     

                                2.2.4 Expert Validation  

                2.3 Analysis Design                         

                2.4 Study Timeline                          

3. Overview                                      

                3.1 Executive Summary                

                3.2 Key Inferences                         

                3.3 New Developments                

4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)                                      

                4.1 Market Drivers                          

                4.2 Market Restraints                    

                4.3 Key Challenges                         

                4.4 Current Opportunities in the Market               

5. Market Segmentation                                              

                5.1 By Disease                  

                                5.1.1 Arteriosclerosis     

                                5.1.2 Cardiac arrhythmias            

                                5.1.3 Myocardial infarction         

                                5.1.4 Acute Coronary Syndrome

                                5.1.5 Peripheral artery disease  

                                5.1.6 Coronary artery disease    

                                5.1.7 Hypertension        

                                5.1.8 Hyperlipidaemia   

                                5.1.9 Thrombosis            

                                5.1.10 Cardiac failure diseases  

                                5.1.11 Others   

                5.2 By Drug Class                             

                                5.2.1 Monotherapies     

                                5.2.2 Combinatiob Therapies     

6. Geographical Analysis                                              

                6.1 Introduction                              

                6.2 Brazil                             

                6.3 Mexico                         

                6.4 Argentina                    

                6.5 Rest of Latin America                             

7. Pipeline Product Analysis                                        

                7.1 Overview                                    

                7.2 Pipeline Development Landscape                                     

                7.3 Molecular Targets in the Pipeline                                     

                7.4 Clinical Trials                              

                                7.4.1 Failure Rate by Stage of Development, Indication, Molecule Type and Molecular Target       

                                7.4.2 Clinical Trial Duration by Stage of Development, Indication, Molecule Type and Molecular Target                 

                                7.4.3 Clinical Trial Size by Stage of Development, Indication, Molecule Type and Molecular Target.               

8. Strategic Analysis                                       

                8.1 PESTLE analysis                         

                                8.1.1 Political     

                                8.1.2 Economic 

                                8.1.3 Social         

                                8.1.4 Technological         

                                8.1.5 Legal          

                                8.1.6 Environmental      

                8.2 Porter’s Five analysis                              

                                8.2.1 Bargaining Power of Suppliers        

                                8.2.2 Bargaining Power of Consumers    

                                8.2.3 Threat of New Entrants     

                                8.2.4 Threat of Substitute Products and Services

                                8.2.5 Competitive Rivalry within the Industry      

9. Market Leaders' Analysis                                        

                9.1 AstraZeneca               

                                9.1.1 Overview

                                9.1.2 Product Analysis   

                                9.1.3 Strategic Evaluation and Operations            

                                9.1.4 Financial analysis  

                                9.1.5 Legal issues            

                                9.1.6 Recent Developments       

                                9.1.7 SWOT analysis       

                                9.1.8 Analyst View          

                9.2 Novartis                       

                9.3 Bristol-Myers Squibb                              

                9.4 Pfizer                            

                9.5 Sanofi                           

                9.6 Merck                           

                9.7 Bayer                            

                9.8 Takeda                         

                9.9 Boehringer Ingelheim                            

                9.10 Johnson & Johnson                              

10. Competitive Landscape                                         

                10.1 Market share analysis                          

                10.2 Merger and Acquisition Analysis                     

                10.3 Agreements, collaborations and Joint Ventures                       

                10.4 New Product Launches                       

11. Expert Opinions                                        

                11.1 Market Outlook                     

                11.2 Investment Opportunities                 

Appendix                                           

                a) List of Tables                

                b) List of Figures                              

  • Regional and country-level analysis and forecasts of the study market; providing Insights on the major countries/regions in which this industry is blooming and to also identify the regions that are still untapped
  • Segment-level analysis in terms of technology, component, and type along with market size forecasts and estimations to detect key areas of industry growth in detail
  • Identification of key drivers, restraints, opportunities, and challenges (DROC) in the market and their impact on shifting market dynamics
  • Study of the effect of exogenous and endogenous factors that affect the global market; which includes broadly demographic, economics, and political, among other macro-environmental factors presented in an extensive PESTLE Analysis
  • Study the micro environment factors that determine the overall profitability of an Industry, using Porter’s five forces analysis for analysing the level of competition and business strategy development
  • A comprehensive list of key market players along with their product portfolio, current strategic interests, key financial information, legal issues, SWOT analysis and analyst overview to study and sustain the market environment
  • Competitive landscape analysis listing out the mergers, acquisitions, collaborations in the field along with new product launches, comparative financial studies and recent developments in the market by the major companies
  • An executive summary, abridging the entire report in such a way that decision-making personnel can rapidly become acquainted with background information, concise analysis and main conclusions
  • Expertly devised analyst overview along with Investment opportunities to provide both individuals and organizations a strong financial foothold in the market
  1. Latin America Cardiovascular Therapeutic Drugs Market, By Region, From 2020 to 2025 (USD Billion)            
  2. Latin America Cardiovascular Therapeutic Drugs Market, By Disease, From 2020 to 2025 (USD Billion)          
  3. Latin America Arteriosclerosis Market, By Region, From 2020 to 2025 (USD Billion)
  4. Latin America Cardiac arrhythmias Market, By Region, From 2020 to 2025 (USD Billion)      
  5. Latin America Myocardial infarction Market, By Region, From 2020 to 2025 (USD Billion)    
  6. Latin America Acute Coronary Syndrome Market, By Region, From 2020 to 2025 (USD Billion)          
  7. Latin America Peripheral artery disease Market, By Region, From 2020 to 2025 (USD Billion)             
  8. Latin America Coronary artery disease Market, By Region, From 2020 to 2025 (USD Billion)
  9. Latin America Hypertension Market, By Region, From 2020 to 2025 (USD Billion)    
  10. Latin America Hyperlipidaemia Market, By Region, From 2020 to 2025 (USD Billion)              
  11. Latin America Thrombosis Market, By Region, From 2020 to 2025 (USD Billion)       
  12. Latin America Cardiac failure diseases Market, By Region, From 2020 to 2025 (USD Billion)
  13. Latin America Cardiovascular Therapeutic Drugs Market, By Drug Class, From 2020 to 2025 (USD Billion)     
  14. Latin America Monotherapies Market, By Region, From 2020 to 2025 (USD Billion)
  15. Latin America Combination Therapies Market, By Region, From 2020 to 2025 (USD Billion)
  16. Brazil Cardiovascular Therapeutic Drugs Market, By Disease, From 2020 to 2025 (USD Billion)          
  17. Brazil Cardiovascular Therapeutic Drugs Market, By Drug Class, From 2020 to 2025 (USD Billion)     
  18. Argentina Cardiovascular Therapeutic Drugs Market, By Disease, From 2020 to 2025 (USD Billion)  
  19. Argentina Cardiovascular Therapeutic Drugs Market, By Drug Class, From 2020 to 2025 (USD Billion)            
  20. Mexico Cardiovascular Therapeutic Drugs Market, By Disease, From 2020 to 2025 (USD Billion)       
  21. Mexico Cardiovascular Therapeutic Drugs Market, By Drug Class, From 2020 to 2025 (USD Billion) 

Please wait. . . . Your request is being processed

Related Reports

LICENCE TYPE

$ 1234 2875

Clients
clients
clients
clients
clients
clients
clients
Click for Request Sample